Association Between Genetic Variant Scores and Warfarin Effect (AWARE1)

C

Cipherome

Status

Completed

Conditions

Pulmonary Embolism
Atrial Fibrillation
Deep Vein Thrombosis
Venous Thromboembolic Disease
Intracardiac Thrombus

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03894878
C01-001 SC001

Details and patient eligibility

About

Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥ 4, bleeding event, ischemic stroke, death) in participants taking warfarin for atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and/or intracardiac thrombosis.

Full description

It is anticipated that next generation genomic sequencing will identify rare genetic variants in ethnically diverse populations, which otherwise would not have been detected using commercially available warfarin tests. Furthermore, retrospective review of clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥ 4, major bleeding event, ischemic stroke) of study participants will determine the clinical utility of genetic variant risk scores. Study outcomes will provide guidance on future directions for optimizing dosing algorithms for warfarin that combine pharmacogenetic principles with clinical dosing.

Enrollment

200 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Non-valvular atrial fibrillation
  • Deep venous thrombosis (DVT) and/or pulmonary embolism (PE) with no hypercoagulable condition
  • Non-valvular atrial fibrillation and DVT/PE (with no hypercoagulable condition)
  • Intracardiac thrombosis (i.e. apical thrombosis, atrial thrombosis, auricular thrombosis, mural thrombosis, and/or ventricular thrombosis)
  • Age 18-99 years
  • Signed informed consent

Exclusion criteria

  • Presence of a mechanical heart valve
  • Failure to provide signed informed consent
  • Known diseases that affects coagulation test results such as vitamin K deficiency, disseminated intravascular coagulopathy, Von Willebrand disease, hemophilia, liver failure, etc.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems